Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Current Deferred Revenue (2018 - 2025)

INVO Fertility (IVF) has disclosed Current Deferred Revenue for 8 consecutive years, with $720407.0 as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue rose 28.09% to $720407.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $720407.0 through Sep 2025, up 28.09% year-over-year, with the annual reading at $602359.0 for FY2024, 47.36% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $720407.0 at INVO Fertility, down from $834850.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $3.4 million in Q1 2021, with the low at $5793.0 in Q1 2022.
  • Average Current Deferred Revenue over 5 years is $544797.6, with a median of $416745.0 recorded in 2024.
  • Peak annual rise in Current Deferred Revenue hit 1931.8% in 2022, while the deepest fall reached 99.83% in 2022.
  • Over 5 years, Current Deferred Revenue stood at $5900.0 in 2021, then soared by 1931.8% to $119876.0 in 2022, then skyrocketed by 240.99% to $408769.0 in 2023, then skyrocketed by 47.36% to $602359.0 in 2024, then rose by 19.6% to $720407.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $720407.0, $834850.0, and $725330.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.